A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

I have suffered from cystic acne for years but I think I've finally found a product that is helping to clear up my stubborn acne.

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

NARBERTH, Pennsylvania (WPVI) -- "Take A Breather Foundation" based in Narberth is a stress relief outlet for people with cystic fibrosis. Their focus is to provide a "breather" to their recipients, ...

The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people in the U.S. currently have it, "though this is likely an ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...